RxDoctor Payments Data

Allison Cherry, MD

Internal Medicine · Somerset, KYNPI 1871599399

Payments from drug & device makers

$1,960in general payments, 2019–2025

Across 143 payments — averaging $13.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$388
  • Kowa Pharmaceuticals America, Inc.$345
  • Abbott$216
  • Sanofi-aventis U.S. LLC$195
  • Lilly USA, LLC$177
  • Amgen$96
  • plus $544 from 15 others

What the payments were for

  • Food & beverage$1,960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,960 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$93,637
Medicare patients
547
Services billed
2,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$138,265
OzempicSemaglutide40$62,875
JardianceEmpagliflozin51$61,157
TrulicityDulaglutide32$54,304
EliquisApixaban24$31,721
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$26,219
LinzessLinaclotide19$22,685
JanuviaSitagliptin Phosphate25$13,758
FarxigaDapagliflozin Propanediol15$12,202
Repatha SureclickEvolocumab15$12,166
RybelsusSemaglutide11$11,925
Janumet XrSitagliptin Phos/Metformin Hcl13$6,810
SynthroidLevothyroxine Sodium92$5,488
Levothyroxine Sodium377$4,899
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$177$192,569139 claims
Novo NordiskOzempic, Rybelsus$58$74,79951 claims
Boehringer IngelheimJardiance$53$61,15751 claims
PfizerEliquis$388$31,72124 claims
AbbVieLinzess, Synthroid$15$28,173111 claims
MerckJanuvia, Janumet Xr$50$20,56738 claims
AstraZenecaFarxiga$53$12,20215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →